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Salvage treatment and survival for relapsed follicular lymphoma following 
primary radiotherapy: A collaborative study on behalf of ILROG 
 
BLINDED MANUSCRIPT 
 
ABSTRACT: 
Purpose/Objective(s):  
We previously reported ~30% of patients with localized follicular lymphoma (FL) 
staged by 18F-FDG-PET-CT (PET-CT) receiving primary radiotherapy (RT) will 
relapse within 5 years. We sought to report outcomes for those who relapsed.  
 
Materials/Methods:  
We conducted a multicenter retrospective study of patients who received 
RT≥24Gy for stage I-II FL grade 1-3A FL, with age≥18 years, and PET-CT 
staging. Observation was defined as >6 months without treatment from relapse. 
Overall survival (OS) and freedom from progression (FFP) were estimated with 
Kaplan-Meier, and uni- and multivariable analyses (MVA) with Cox regression.  
 
Results:  
Of 512 patients with median follow up of 52 months, 149 (29.1%) developed 
recurrent lymphoma at a median 23 months (range, 1-143) after primary RT. 
Median follow up was 33 months post relapse. 3-year OS was 91.4% after 
recurrence. OS was significantly worse for those with relapse ≤12 months from 
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date of diagnosis versus all others, 88.7% versus 95.8%, respectively (p=0.01), 
and remained significantly worse on MVA (FLIPI-adjusted HR=3.61, p=0.009). 
Histology at relapse included: 93 indolent (grade 1-3A), 3 FL grade 3B/NOS, 18 
diffuse large B-cell lymphoma (DLBCL); 35 patients were not biopsied. Of those 
with follow up ≥3 months and biopsied (n=74) or presumed (n=23) indolent 
recurrence, 58 patients (59.8%) were observed, 19 (19.6%) had systemic 
therapy, 16 (16.5%) RT, and 4 (4.1%) systemic therapy+RT. For patients with 
indolent recurrences that were observed, 3-year FFP or freedom from treatment 
was 56.6% (median, 48 months). For all patients with biopsied/presumed 
indolent recurrence receiving salvage treatment (n=59, including 20 initially 
observed) 3-year FFP was 73.9%. 
 
Conclusions:  
Prognosis for patients with relapsed FL following primary radiotherapy is 
excellent supporting the role of primary radiation in the management of early 
stage disease. Patients with localized FL treated with primary RT who experience 
early relapse (<12 months) have inferior survival to those with longer disease-
free interval.  
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INTRODUCTION: 
 
     For patients with localized follicular lymphoma (FL), primary radiotherapy may 
be curative, with historical cohorts demonstrating freedom from relapse of 
approximately 40-50% with long term follow up (1). We previously reported that 
with PET-CT staging, the curative potential of definitive radiotherapy is likely to 
be higher than previously thought, with 5-year freedom from progression of 
approximately 74% for stage I and 49% for stage II (2). However, 30-50% of 
patients will develop relapse, and the optimal management for relapsed follicular 
lymphoma is not well defined.  
      Repeat radiotherapy may be an option in the uncommon setting of local 
recurrence, which occurs <10% of the time after definitive radiotherapy, or for 
limited relapse, i.e., ‘relapse stage I-II’. Clinical judgement is crucial in identifying 
patients eligible for repeat definitive radiotherapy, ≥24 Gy, which is reasonable 
for treatment of local/marginal recurrence or for localized relapse encompassing 
a limited RT field assuming they responded initially to primary RT (3, 4).  
     In the vast majority of cases, relapsed FL after definitive radiotherapy occurs 
distantly (outside of the prescribed dose volume) at which point management is 
frequently adapted from that of de novo advanced stage disease. This may 
include observation, rituximab monotherapy, and immunochemotherapy (5, 6). 
Additionally, low dose radiotherapy offers high local control for symptomatic sites 
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of involvement (7). The challenge in managing these patients lies in identifying 
those who will have indolently behaving disease appropriate for observation 
versus those that will have an aggressive course. However, there is mounting 
evidence that patients with stage III-IV follicular lymphoma who develop 
progressive disease within 1-2 years after diagnosis have inferior survival 
compared to others (8, 9). It is not clear if early progression has the same 
significance in early stage disease treated with RT. 
     Given limited data, particularly from the rituximab era, we sought to evaluate 
outcomes following relapse for a large cohort of patients treated with definitive 
radiotherapy alone for early stage follicular lymphoma.  
 
METHODS/MATERIALS: 
 
Patients 
     We conducted a multi-institutional retrospective review under the sponsorship 
of the International Lymphoma Radiation Oncology Group (ILROG). Following 
individual institutional review board (IRB) approvals, 16 centers submitted de-
identified patient cases meeting our prospectively defined inclusion criteria: 1) 
grade 1-3A follicular lymphoma, 2) stage I-II, 3) staging that included 18F-
fluorodeoxyglucose PET-CT, 4) RT dose equivalent to at least 24 Gy/12 fractions, 
5) post-treatment follow up of ≥3 months, and 6) no prior radiotherapy or 
systemic therapy. We collected detailed baseline characteristics and primary 
radiotherapy details as reported previously including the follicular lymphoma 
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international prognostic index (FLIPI, which includes age, >4 nodal sites, LDH 
elevation, serum hemoglobin<12 g/dL, and advanced stage) (2).  
 
Relapse, salvage treatment and outcomes assessment 
 
     We collected detailed information at time of relapse, including: method of 
detection (clinical symptoms, physician exam, radiographic detection), age at 
recurrence, location of recurrence including relation to radiotherapy volume (local, 
marginal at or near RT edge, or distant outside of the prescribed dose field), 
biopsy status and pathology of recurrence, salvage treatment, and response to 
salvage treatment by clinical and when available radiographic assessment. 
Limited recurrence was defined as 1-2 sites of involvement (Ann Arbor nodal or 
extranodal) or extent of disease suitable for radiation monotherapy. Observation 
was defined as >6 months from relapse without treatment. Progressive disease 
was scored by clinical, radiographic or pathologic evidence. Lymphoma 
refractory to initial primary RT was defined as recurrence within the RT 
prescription dose volume without having achieved clinical or radiographic 
response within 6 months post-treatment.  
 
End points and outcomes assessments 
 
     We measured OS for all patients with relapse from date of recurrence. To 
evaluate the impact of early relapse, we compared overall survival (OS) for those 
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experiencing relapse within 12- and 24-months versus all others (8, 9). For this 
analysis, OS time was measured from date of relapse or 12- and 24-months after 
pathologic diagnosis to avoid immortal time bias as per methods by Casulo et al. 
(9). There was no competing risk of death within 24 months from initial diagnosis 
to progression or relapse event.  
      For patients with follow up ≥3 months following diagnosis of relapse, we 
measured freedom from progression or next treatment as the time interval from 
date of clinical, radiographic or pathologic recurrence for those observed and 
date of treatment completion for those receiving salvage treatment.  
 
Statistical analyses 
 
     We used the Kaplan-Meier method to measure FFP or time to next treatment 
and OS with stratification evaluated with the log-rank test. When measuring FFP, 
only 4 deaths occurred prior to an additional progression event (only 2 prior to 3 
years of follow up) representing minimal competing risk with insignificant impact 
on our estimate of FFP. We did not statistically compare FFP for subgroups 
receiving observation, lower intensity treatment (rituximab monotherapy or low 
dose radiation), or intense treatment (definitive radiation or chemotherapy) as full 
baseline patient factors at time of relapse were not available nor was the 
justification for selected treatment decision. Univariable and multivariable hazard 
ratios (HR) were calculated using Cox regression analysis with corresponding 
Wald 95% confidence intervals (95% CI) and p-values. We conducted 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
multivariable analyses for patient factors meeting significance of p<0.05 on 
univariable analysis without exceeding approximately 1 variable per 10 events in 
each model. Statistical analysis was performed using SAS version 9.3 (SAS 
institute, Cary, North Carolina) and R version 3.4 (Vienna, Austria). All p-values 
were two-sided, and considered significant at p < 0.05. 
 
 
RESULTS:  
 
Overall survival after relapse 
     Of 512 patients with median follow up of 52 months, 149 (29.1%) developed 
relapsed lymphoma at a median 23 months (range, 1-143) after primary RT 
(Figure 1). The 3-year OS for patients with relapse after primary RT was 91.4% 
(Figure 2A, 95% CI=84.9-95.2%) with 16 deaths occurring during follow up (n=8 
lymphoma specific deaths, n=3 other causes, and n=5 unknown). Median follow 
up was 33 months post relapse. 137 (91.9%) recurrences occurred outside of the 
prescription treatment volume at distant sites. Histology at the time of relapse 
included: 93 indolent (n=89 follicular lymphoma grade I-IIIA, n=2 primary 
cutaneous follicle center lymphoma, n=1 nodal marginal zone lymphoma), 3 FL 
grade 3B/NOS, 18 diffuse large B-cell lymphoma (DLBCL); 35 patients were not 
biopsied. Thus, we observed that 19 of 149 patients (12.8%) with relapsed 
lymphoma had biopsy proven large cell transformation to DLBCL (including one 
patient that initially had low grade recurrence at first relapse).  
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     We compared survival for patients with early relapse versus all others. As 
demonstrated in Table 1, patients with relapse ≤12 months were more likely to 
have initial stage II FL (p=0.01) and higher ECOG performance score (p=0.03) 
but no difference in age, gender or FLIPI. No patient in this analysis had 
recurrent lymphoma refractory to initial primary RT (see Methods/Materials 
section for definition of refractory). As Figure 2B demonstrates, 3-year OS was 
significantly worse for those with relapse ≤12 months (n=28) versus no relapse 
≤12 months (n=468) from date of diagnosis, 88.7% (95% CI=69.0-96.2%) versus 
97.6% (95% CI=95.4-98.8%), respectively (p=0.01). This association persisted 
for those recurring within 2 years of diagnosis with significantly worse 3-year OS 
for those with relapse≤24 months (n=69) versus no relapse ≤24 months (n=377), 
91.8% (95% CI=81.4-96.5%) versus 97.0% (95% CI=94.0-97.5), respectively 
(Figure 2C, p=0.048).  
     We next performed univariable and multivariable Cox regression comparing 
survival for patients with relapse ≤12 months versus all others. On univariable 
analysis, FLIPI (HR=1.99, 95% CI=1.13-3.51, p=0.02) and relapse ≤12 months 
(HR=3.39, 95% CI=1.36-8.47, p=0.009) were significantly associated with 
survival. On MVA, both FLIPI (HR=2.00, 95% CI=1.13-3.52, p=0.02) and relapse 
≤12 months (HR=3.61, 95% CI=1.38-9.45, p=0.009) significantly associated with 
survival. We did not observe significant association on univariable analysis 
between overall survival and gender, initial stage, or ECOG PS. Although we 
observed similar findings on univariable analysis for patients with relapse ≤24 
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months, the FLIPI-adjusted multivariable model showed only trend between 
relapse ≤24 months and OS (Table 2). 
  
Outcomes for patients with indolent relapse and follow up ≥3 months 
 
     97 patients had biopsied (n=74) or presumed (n=23) indolent recurrence and 
follow up ≥3 months (median follow up 36.9 months). Notably, only 1 patient who 
relapsed within 12 months of diagnosis was lost to follow up. Baseline 
characteristics are summarized in Table 1 and patients were managed as 
follows: 58 (59.8%) observation, 19 (19.6%) systemic therapy, 16 (16.5%) RT, 
and 4 (4.1%) systemic therapy and RT. For many cases, radiographic details 
provided by individual institutions at time of relapse were limited. For example, as 
listed in Table 1, the total number and location of nodal and extranodal sites 
involved with relapsed lymphoma were not available for 28.9% of cases.  
     There was no difference in OS between patients who received immediate 
salvage treatment versus observation (p=0.28). Additionally, there was no 
significant survival difference for patients who had relapse ≤12 months who 
underwent immediate treatment versus those who were observed (log-rank 
p=0.34). As shown in Figure 3A, 3-year FFP and/or freedom from treatment was 
82.3% (95% CI=64.4-91.8%) for those who received immediate salvage 
treatment (n=39) and was 56.6% (95% CI=40.5-69.9%) for those selected for 
observation (n=58). The FFP estimates for the subset of patients with relapse 
within 12 months were similar: 83.3% (95% CI=27.3-97.7%) for those who 
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received immediate salvage treatment (n=6) and 42.3% (95% CI=13.8-69.1%) for 
those selected for observation (n=14). There was no significant difference in age, 
gender, localized relapses, biopsy status, or symptoms between subgroups 
(Supplemental Table 1). For those observed, median time to treatment or 
progression was 48 months (range, 8-56) with 20 receiving salvage treatment at 
a median of 21 months with continued observation for the remainder. 
     For all patients with indolent recurrence receiving salvage treatment (n=59), 3-
year FFP was 73.9% (95% CI=58.8-84.2%). 35 completed intensive treatment 
with 3-year FFP of 94.7% (95% CI=68.1-99.2%) (Figure 3B). Intensive treatment 
included the use of definitive radiotherapy for localized recurrence (n=14 with 
RT≥24 Gy), rituximab (R)-chemotherapy (n=2 with 8 cycles R-
cyclophosphamide/vincristine/prednisolone [R-CVP], n=5 with 6 cycles R-
cyclophosphamide/hydroxydaunorubicin/oncovin/prednisolone [R-CHOP] with 
maintenance R for n=4, n=1 with R-zevalin, n=1 with 5 doses of anti-CD20 
vaccine trial, n=6 with 6 cycles R-bendamustine, n=2 with 6 cycles R-CVP, n=1 
with 6 cycles R-lenalidomide), or systemic therapy and RT (n=1 with R-
CHOP+39.6 Gy, n=1 with 4 doses of rituximab+30 Gy, n=1 with R-CVP+21 Gy). 
Only 2 patients who received intensive treatment developed second recurrence 
during median follow up of 33 months (range 3.3-87.8). 24 patients received 
more palliative therapy with RT<24 Gy or rituximab alone (n=8 with RT<24 Gy, 
n=1 with rituximab+4 Gy, and n=15 with rituximab monotherapy with median of 4 
doses, range 4-24) with 3-year FFP of 51.7% (95% CI=29.4-70.1%) (Figure 3B). 
There was no significant difference in age, gender, limited recurrences, biopsy 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
status, or symptoms between subgroups (Supplemental Table 2), but there was 
a significantly lower rate of distant relapse in the cohort receiving intensive 
treatment corresponding with the small number of patients salvaged with local 
recurrence (p=0.01). We did not observe significant association between age, 
gender, relapse ≤12 months, patient symptoms, limited recurrence, or imaging 
detected recurrence and the outcome FFP (Supplemental Table 3). 
     Of those with localized recurrence, 8 patients had isolated local (n=6 within 
prior high dose RT field) or marginal (n=2, at high dose RT field edge) 
recurrences at a median of 19.2 months following primary RT (range 15-58.9). All 
8 patients initially had a complete response either clinically (n=2), by CT (n=1), or 
PET-CT (n=5, all with complete metabolic and size response) within 6 months of 
completing treatment. 4 were initially observed with 2 ultimately receiving salvage 
treatment at 9 and 10 months with 24 Gy and 6 cycles R-CHOP, respectively, 
without further progression. The other 4 patients underwent immediate treatment 
with radiotherapy alone (n=2, 36 Gy), radiotherapy (24 Gy) with rituximab, and 6 
cycles of R-CHOP. None of the 6 patients who received salvage treatment for 
local and marginal recurrence had subsequent progression during follow up.  
 
Outcomes for patients with high grade recurrence and large cell 
transformation and follow up ≥3 months 
 
     2 patients with follow up ≥3 months developed grade 3B relapsed FL. One 
was observed with 32 months of follow up without progressive disease and the 
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other received 6 cycles of R-CHOP with partial response by CT imaging and 
subsequently received high dose chemotherapy followed by bone marrow 
transplant 6 months after relapse. 
     10 patients experienced large cell transformation to DLBCL with follow up ≥3 
months and received salvage treatment (n=5 with 6 cycles of R-CHOP, n=1 with 
8 cycles R-CVP, n=1 with 6 cycles of R-CHOP and 4 Gy, n=1 2 cycles R-CHOP 
and 3 cycles R-
etoposide/prednisone/oncovin/cyclophosphamide/hydroxydaunorubicin, n=1 with 
unknown systemic therapy and 30 Gy, and n=1 enrolled on an anti-CD20 vaccine 
trial) from which 6 remain disease free with median follow up of 28 months 
(range, 6.4 – 74.0). 1 patient experienced transformation to DLBCL after initially 
being observed for biopsy proven low grade relapsed FL for 14 months at which 
point she received low dose radiotherapy (4 Gy) with transformation occurring 30 
months after radiotherapy.  
 
Discussion:  
 
     Taken together with our prior report (2), our results demonstrate that a third of 
patients with predominantly stage I follicular lymphoma will develop relapse after 
primary radiotherapy but for whom overall survival is excellent in the modern era. 
The excellent prognosis observed for this relapse cohort emphasizes that 
primary radiation for localized follicular lymphoma is an excellent treatment 
option. Although the recently reported randomized TROG 9903 trial showed 
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progression free survival benefit for patients receiving adjuvant rituximab based 
chemotherapy after radiation for early stage follicular lymphoma (10), given the 
excellent prognosis, including that for those with relapse, adjuvant systemic 
therapy may lead to overtreatment for many patients.  
     In our cohort, treatment strategy for those with indolent recurrence varied 
widely and with short follow up, we were unable to detect differences in survival 
with each approach. Thus, any decision to offer treatment at time of relapse must 
be weighed with the risk of acute and late adverse effects. Greater than 60% of 
patients in our cohort with indolent recurrence who underwent salvage treatment 
received rituximab, likely contributing to the excellent outcomes. However, nearly 
60% of patients with indolent recurrence who were observed did not have 
disease progression nor receive treatment within 3 years. For those with low 
grade and indolent behaving follicular lymphoma, patients selected for intensive 
treatment with definitive radiotherapy or immuno-chemotherapy enjoyed a 
durable response. Although patients in our series had a limited median follow up 
of ~3 years, large historical cohorts demonstrate the majority of recurrences 
occur within 3-5 years after salvage treatment (11, 12). Additionally, surrogate 
endpoints in identifying relapse earlier than clinical or radiographic progression 
are being investigated for which our data may inform further study design (13). 
     Large studies investigating management and outcomes for patients with 
recurrent follicular lymphoma after primary RT in the rituximab era are not 
available. In a pre-rituximab cohort from Stanford, 70.9% were identified as 
relapse stage I-II (11), with increasing age, >=3 relapse sites associated with 
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worse FFP. In our series, we were unable to identify patient factors at relapse 
associated with worse FFP. Rituximab was given to more than half of the 
patients in our series, which may in part explain why variables such as 
widespread recurrence (>=3 relapse sites) were not associated with subsequent 
progression. In the Stanford series, increasing age, transformation, and >=3 sites 
were significantly associated with worse OS in multivariable model. Another pre-
rituximab era large single institution series showed increasing age and number of 
prior treatments was associated with worse OS (12). The survival following 
relapse for patients in our cohort was excellent, 91.4% at 3 years, and did not 
differ for patients with low grade relapse based on management strategy. 
Although subset OS for patients with initial stage I FL who relapse in the 
LymphoCare study is not readily available, our results are consistent with the OS 
rate for all patients in the LymphoCare cohort with stage I FL who underwent 
PET-CT staging (>90% at 5 years) (14). 
     Given the indolent nature of FL, observation is typically offered in the de novo 
advanced stage or relapse setting. In a randomized controlled trial comparing 
watchful waiting to rituximab monotherapy in patients with low grade and low 
volume follicular lymphoma, approximately half of those being observed 
underwent treatment with systemic therapy (4% of which included rituximab 
monotherapy) or radiotherapy at 3 years of follow up compared with only 12-22% 
receiving induction or maintenance rituximab (5). Our results are similar. Among 
the 60% of patients selected for observation in our cohort, only about 1/3 
required treatment within 3 years. Additionally, there is evidence that patients 
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with FL selected for observation do not have a higher rate of transformation 
compared to those who receive immediate treatment (15). Although our cohort 
has limited follow up, only one patient experienced large cell transformation 
following observation and was salvaged with rituximab-chemotherapy. Thus, 
observation may be a reasonable option for appropriately selected patients with 
the understanding that treatment may be likely, even during short term follow up. 
     Despite evidence that an initial observation period for low grade, advanced 
stage follicular lymphoma, is not associated with a detriment to overall survival, 
patients with early progression have been found to have inferior survival (6, 16). 
This finding was also seen in a cohort of patients with FL managed with 
observation, rituximab monotherapy, and rituximab-chemotherapy, where Mauer 
et al. reported that patients without relapse within 12 months of diagnosis have 
mortality equivalent to an age and sex matched general population cohort (8).  
We also observed that patients in our cohort with early progressive disease from 
date of diagnosis (≤12 or ≤24 months) had significantly inferior survival to those 
with longer disease free interval. Our results are similar to the results seen in the 
LymphoCare study for patients with stage II-IV FL which showed 5 year OS of 
50% for those experiencing early progression of disease versus 90% for the 
reference group (9). We have validated prior evidence suggesting early 
progression is an adverse prognostic factor following relapse after primary 
radiation for early stage FL. We do note that the magnitude of our HR=3.39 for 
relapse ≤12 and worse survival was smaller than that observed for the cohort 
from the LymphoCare study (HR=4.86-8.19), likely reflecting the more favorable 
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patient population in our cohort. Importantly, we found that patients with early 
progressive disease had no difference in response to salvage treatment. 
Additionally, given our short follow up, small number of transformation events, 
and results, it is unclear if immediate or intense treatment translates into a 
disease specific survival benefit. For patients with stage II-IV FL enrolled in the 
FL2000 trial, there was event free and overall survival benefit for patients who 
underwent autologous stem cell transplant at time of first relapse (17). 
     For the rare cases where patients develop local or marginal recurrence 
relative to the initial RT field, reirradiation with definitive radiotherapy may be 
considered. 6 patients in our cohort who underwent reirradiation for marginal or 
local recurrence all had complete response, similar to results reported by others 
(3). Additionally, salvage treatment with definitive radiotherapy alone for selected 
patients with localized recurrence may allow for delay of systemic therapy, 
including rituximab. This may be potentially advantageous given reports of lower 
response rate for patients with transformed FL and DLBCL treated with repeat 
courses of rituximab (18). Results for patients in our series undergoing 
reirradiation complement the 2014 ILROG guidelines for patients with advanced 
stage indolent NHL (4). 
     Our study has several limitations including limited details regarding toxicity, 
incomplete re-staging at relapse (including lack of biopsy confirmation for 35 
patients [23% of those with relapse], LDH, exact number of nodal sites involved 
by relapse, and hemoglobin), 42 patients without follow up after relapse (28% of 
patients with relapse), and short follow up. The end point FFP or freedom from 
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next treatment and the number of patients who did not undergo biopsy of 
recurrence may over-estimate the percent of patients with progressive FL, 
particularly those being observed. Although long-term follow up is crucial for 
assessing outcomes for FL, studies reported prior to implementation of rituximab 
have shown the majority of recurrences occur within 3-5 years after salvage 
treatment (11, 12). At the very least, our results are hypothesis generating in 
providing early outcomes for those with relapsed lymphoma following primary 
radiotherapy for localized FL. 
     Our results highlight that patients with stage I-II follicular lymphoma who are 
treated with curative radiotherapy and experience subsequent relapse have an 
excellent survival.  However, our results also suggest that patients who relapse 
within 1-2 years have worse prognosis, which may aid in the decision as to 
whether or not to offer salvage treatment as opposed to observation.  
 
FIGURE LEGENDS: 
Figure 1. Flow diagram for patient cohort. 
 
Figure 2. Overall survival (OS) for patients with relapsed lymphoma 
following primary radiation for early stage follicular lymphoma. A. KM curve 
shows 3-year OS rate of 91.2% for patients with relapsed lymphoma. B. KM 
curve shows 3-year OS was significantly worse for those with relapse ≤12 
months from date of diagnosis versus others (reference group), 88.7% versus 
97.6%, respectively. C. KM curve shows 3-year OS was significantly worse for 
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those with relapse≤24 months from date of diagnosis versus others (reference 
group), 91.8% versus 97.0%, respectively.  
 
Figure 3. Freedom from progression (FFP) for patients with indolent 
recurrence and follow up ≥3 months stratified by management type. A. FFP 
by initial treatment for indolent relapse. B. 3-year FFP was 94.7% for patients 
selected for intensive salvage treatment, with 3-year FFP 51.7% for those 
selected for RT<24 Gy or rituximab monotherapy. 
 
Table 1. Patient characteristics for those with and without relapse ≤12 months 
 
Table 2. Uni- and multivariable analysis comparing overall survival for patients 
with early relapsed follicular lymphoma following primary radiotherapy for 
localized disease versus all others. 
 
Table 3. Patient characteristics for those with follow up ≥3 months at time of 
relapse. 
 
Supplemental Table 1. Comparison of baseline characteristics for patients 
with indolent relapse after primary RT undergoing observation versus 
immediate treatment (n=97). 
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Supplemental Table 2. Comparison of baseline characteristics for patients 
with indolent relapse after primary RT undergoing salvage treatment (n=59). 
 
Supplemental Table 3. Univariable analysis of prognostic factors for 
patients with indolent recurrence and with follow up ≥3 months at time of 
relapse.  
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Table 1. Patient characteristics for those with and without 
relapse ≤12 months 
Parameter Relapse ≤12 
months 
(n=28) 
No relapse 
≤12 months 
(n=468) 
 
 
p-value 
Median age 
Male 
Initial stage I 
ECOG PS, median 
     0 
     1 
     2 
FLIPI, median 
     0 
     1 
     >1 
 62 (35-83) 
12 (42.9%) 
17 (60.7%) 
0 (0-1) 
21 (75.0%) 
7 (25.0%) 
0 (0%) 
1 (0-3) 
12 (42.9%) 
15 (53.8%) 
1 (3.6%) 
59 (20-90) 
241 (51.5%) 
378 (80.7%) 
0 (0-2) 
431 (92.1%) 
35 (7.5%) 
2 (0.4%) 
1 (0-2) 
230 (49.1%) 
204 (43.6%) 
34 (7.3%) 
0.29 
0.37 
0.01 
0.03 
 
 
 
0.61 
Abbreviations: ECOG PS=Eastern cooperative oncology group performance 
status; FLIPI=Follicular lymphoma international prognostic index. 
* Continuous variables are shown with range and categorical variables with 
percentages in parenthesis 
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Table 2. Uni- and multivariable analysis comparing overall survival for patients with early relapsed follicular 
lymphoma following primary radiotherapy for localized disease versus all others. 
Group   Overall survival  
   
 
 
Model 
 
≤12 months  
 
≤24 months  
No early relapse Deaths/total  
 
 
  19/468 16/377 
Early relapse  Deaths/total 
 
HR 
95% CI 
p 
 
HR 
95% CI 
p 
   
 
Unadjusted 
 
 
 
FLIPI-adjusted 
(MVA) 
5/28 
 
3.39 
1.36-8.47 
0.009 
 
3.61 
1.38-9.45 
0.009 
8/69 
 
2.52 
1.08-5.91 
0.03 
 
2.20 
0.92-5.28 
0.08 
Abbreviations: HR=Hazard ratio; CI = confidence interval; FLIPI=follicular lymphoma international prognostic 
index; MVA=Multivariable analysis including FLIPI and relapse ≤12 months. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 3. Patient characteristics for those with low grade 
recurrence and follow up ≥3 months from date of relapse. 
Parameter Cohort (n=97) 
Median age 
Male 
Biopsy confirmed  
     Yes 
     No (presumed low grade) 
Clinical symptoms  
Failure relative to RT field 
     Local (within RT field) 
     Marginal (at field edge) 
     Distant (outside RT field) 
Number of relapse sites 
     Limited (1 or 2 sites) 
     Advanced (>2 sites) 
     Unknown 
61 (26 - 87) years 
52 (53.6%) 
 
74 (76.3%) 
23 (23.7%) 
25 (25.8%) 
 
6 (6.2%) 
2 (2.1%) 
89 (91.8%) 
 
45 (46.7%) 
24 (24.7%) 
28 (28.9%) 
Initial salvage treatment 
     Observation 
     RT alone 
          <24 Gy 
          ≥24 Gy 
     Rituximab monotherapy 
     Rituximab + RT (4, 24, 30 Gy) 
     Rituximab + chemotherapy 
     R-Chemo + RT (21 Gy) 
 
58 (59.8%) 
16 (16.5%) 
4 (4.2%) 
12 (12.5%) 
8 (8.3%) 
3 (3.1%) 
11 (11.5%) 
1 (1.0%) 
Median follow up from initial failure 
 
36.9 (4.3 – 150.5) 
mo.  
 
Abbreviations: NOS=not otherwise specified., mo.=months 
* Continuous variables are shown with range and categorical variables with 
percentages in parenthesis 
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149 pts with relapse: 
     n=92 indolent recurrence 
     n= 35 un-biopsied 
						n=22 transformed 	
Observation, n=59 
n = 42 indolent 
n = 16 un-biopsied 
(n = 20 ultimately  
received treatment) 
 
n = 1 transformed 
 
Immediate tx, n=48 
n = 32 indolent 
n = 7 un-biopsied 
 
 
n = 9 transformed 
Stage I-II FL staged by PET/CT, n=512 
Lost to follow up, n=42 
n = 19 indolent 
n = 12 un-biopsied 
 
n = 11 transformed 
 
 
n=59 indolent and received salvage tx 
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SUMMARY:  
 
In the modern era, survival for patients with relapsed follicular lymphoma after 
primary radiotherapy for initially localized disease is excellent. Although there are 
many acceptable treatment strategies for relapse, including observation, patients 
with recurrent lymphoma less than 12 months from diagnosis after primary 
radiotherapy appear to have significantly worse OS. Our results may aid in the 
decision to offer treatment immediately following relapsed lymphoma after 
primary radiotherapy for localized follicular lymphoma.   
 
